Articles

CML in pregnancy and childhood.

Posted on Monday, October 15, 2012 - 12:57pm

CML in pregnancy and childhood: Apperley J.

Read more

Ariad Pharmaceuticals: Ponatinib Approval Anticipated In Second-Line CML October 1, 2012

Posted on Wednesday, October 3, 2012 - 12:20pm

Jennifer Landis, Ning Yang, Ph.D., Andrew McDonald, Ph.D.

Read more

Reduced-Intensity Conditioning (RIC) Vs Standard Conditioning pre: Allogeneic Haemopoietic Cell Transplantation in Acute Myeloid Leukaemia in 1st Complete Remission:Lancet Oncol. 2012 Sept 6

Posted on Tuesday, September 25, 2012 - 11:15am

Reduced-Intensity Conditioning Versus Standard Conditioning Before Allogeneic Haemopoietic Cell Transplantation in Patients With Acute Myeloid Leukaemia in First Complete Remission: A Prospective, Open-Label Randomised...

Read more

FDA Approves Bosutinib for Previously Treated CML- 5th September 2012

Posted on Tuesday, September 25, 2012 - 10:03am

FDA Approves Bosutinib for Previously Treated CML IMNG Medical Media. 2012 Sept 5, E Mechcatie

Read more

'Your Blood'- Media Planet Guardian Supplement 12th September 2012

Posted on Thursday, September 13, 2012 - 12:01pm

'Your Blood' An independent supplement distributed by the Guardian on behalf of MediaPlanet who take sole responsibility for its contents.

Read more

2013 European Group for Blood and Marrow Transplantation (EBMT) conference London

Posted on Monday, September 10, 2012 - 5:20pm

In April 2013 the annual European Group for Blood and Marrow Transplantation (EBMT) conference will be held in London. As part of this conference, there is a dedicated Patient and Family Day on Saturday 6 April where...

Read more

Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-Phase CML With T315I Mutation

Posted on Monday, September 10, 2012 - 1:50pm

Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-Phase CML With T315I Mutation Blood. 2012 Aug 15;[Epub Ahead of Print], J Cortes, JH Lipton, D Rea, R Digumarti, C Chuah...

Read more

Ariad Prepares for Early Launch of CML Drug Ponatinib The Pink Sheet Daily. 2012 Aug 6, E Hayes

Posted on Monday, September 10, 2012 - 1:47pm

With an FDA filing of its wholly owned chronic myelogenous leukemia drug ponatinib under its belt, Ariad Pharmaceuticals Inc.says it will be commercially ready in the U.S. by the end of October and hopes to launch in...

Read more

Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells

Posted on Monday, September 10, 2012 - 1:36pm

Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells Br J Cancer. 2012 May 1;1061772-1778, J Wang, TP Hughes,

Read more

Brian Druker: My Vision for CML and the Road to a Cure

Posted on Tuesday, August 21, 2012 - 11:28am

Thanks to Andrew Schorr of Patient Power who produced the following video interview with Brian Druker MD.

Read more

Ariad Announces Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration

Posted on Thursday, August 16, 2012 - 4:29pm

'Results from the ongoing Phase 2 PACE trial of ponatinib reported in June at this year’s annual meeting of the American Society of Clinical Oncology showed that 54 percent of chronic-phase CML patients who were...

Read more